Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as C$0.86 and last traded at C$0.88, with a volume of 6500 shares traded. The stock had previously closed at C$0.90.
Oncolytics Biotech Stock Performance
The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The company has a market cap of C$65.51 million, a price-to-earnings ratio of -2.37 and a beta of 1.35. The stock has a 50-day moving average price of C$1.02 and a 200 day moving average price of C$1.27.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 03/24 – 03/28
- How to trade using analyst ratings
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Golden Cross Stocks: Pattern, Examples and Charts
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
